SINTX Technologies Sells TA&T Subsidiary, Shifts Focus to Medical Device Market
Salt Lake City, UT, February 20, 2025 – SINTX Technologies, Inc. (NASDAQ: SINT), a leader in advanced ceramics for medical applications, today announced a strategic move to enhance its focus on the medical device sector. The company has sold its wholly-owned subsidiary, Technology Assessment and Transfer (TA&T), to Tethon Corporation DBA Tethon 3D (Tethon).
This transaction is designed to streamline SINTX’s operations, improve its financial flexibility, and accelerate innovation in the healthcare field. The sale of TA&T aligns with SINTX’s strategic goals by allowing the company to concentrate its resources on commercializing its bioceramic technologies, with their potential to improve patient outcomes and enhance the performance of medical implants and devices.
The divestiture will have a direct positive impact on SINTX’s financial health by reducing corporate liabilities by $750,000 and lowering annual operating expenses by more than $1.7 million.
“This sale represents an important milestone in our strategic realignment,” said Eric K. Olson, CEO of SINTX Technologies. “By divesting of these assets, we are fully committing our resources to the medical device market, where our expertise in advanced ceramics can have the greatest impact. This transaction not only enhances our financial flexibility but also supports our efforts to accelerate product development and commercialization efforts in healthcare.”
SINTX Technologies is dedicated to advancing its proprietary silicon nitride-based technologies, which have been used in human implants since 2008. This renewed emphasis on healthcare innovation underscores SINTX’s confidence in its core technologies and their ability to drive long-term value creation.
About SINTX Technologies, Inc.
SINTX Technologies, located in Salt Lake City, Utah, is an advanced ceramics company focused on the development and commercialization of materials, components, and technologies for medical applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, with products implanted in humans since 2008. Over the past several years, SINTX has utilized strategic acquisitions and alliances to expand into new markets. For more information, visit www.sintx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties which could cause actual results to differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements.
Contact
For business and media inquiries, contact: SINTX Technologies 801.839.3502 IR@sintx.com
